Neuron23

Happy #AdministrativeProfessionalsDay to Teri Ritz, our senior executive assistant! Teri is the glue that holds everything together, keeping our offices and operations running effortlessly. Today and every day, we’re grateful for the essential work that administrative professionals do, and Teri is no exception.

Today is #WorldParkinsonsDay and we’re joining the global effort to raise awareness and end the stigma surrounding Parkinson’s disease.     Parkinson’s is the fastest-growing and the second most prevalent neurological condition, affecting an estimated 11.8 million people worldwide. At Neuron23, we are deeply committed to improving the lives of those facing #Parkinsons. Our work focuses on slowing disease progression and enhancing patient outcomes, with a dedication to transforming the future of treatment through innovation and collaboration.     By working together, we can pave the way for a future where Parkinson’s no longer limits the potential of those affected.  

Members of Neuron23’s leadership team attended #ADPD2025 in Vienna last week, joining experts to explore the latest in #neurodegenerative disease research. We remain committed to driving innovation in #Parkinsons treatment with a more precise and potentially more effective approach that can enhance and improve the lives of the patients we serve.  

April is #ParkinsonsAwarenessMonth, and we’re honored to highlight our recent visit from patient advocates Lynn and Cherry from the Parkinson's Foundation. Their team shared valuable insights on how events like Moving Day make a meaningful impact on the Parkinson’s community. Hearing firsthand from patients about their journey and advocacy was truly inspiring.   We’re proud to support their mission to improve care and advance research toward a cure, and as part of our partnership, we’re excited to participate in Moving Day San Jose this May. Join us in supporting this important cause here: https://lnkd.in/gEjc8kwp

We are moving beyond the “one-size-fits-all” approach to #Parkinsonsdisease treatment. Through innovation in #precisionmedicine in neurology – including a proprietary companion diagnostic and digital biomarker solutions, enabled by strategic partnerships - we are advancing our NEULARK trial evaluating our LRRK2 inhibitor NEU-411 in patients with genetic signatures linked to increased LRRK2 activity (which we call LRRK2-driven Parkinson’s disease).     In a recent Clinical Leader feature, our Chief Medical Officer Sam Jackson, M.D., shares how our collaborations with Qiagen, Quest Diagnostics, Roche and Sano Genetics are helping to shape the future of targeted treatments for PD. Read more here: https://lnkd.in/gbh9xGmF 

We are incredibly proud to celebrate our CEO Nancy Stagliano for being named one of the Most Influential Women in Bay Area Business 2025 by the San Francisco Business Times.    Nancy’s leadership at Neuron23 is driving groundbreaking advancements in precision medicine, with the goal of transforming the lives of patients with #neurodegenerative and autoimmune diseases. Her vision, innovation, and dedication continue to shape the future of biotech, and we’re honored to have her leading the way.    Please join us in congratulating Nancy and the incredible women who earned this well-deserved recognition! View the full list here: https://lnkd.in/gMFH4Tkt 

We’re pleased to share that a manuscript has been published today in The Proceedings of the National Academy of Sciences (PNAS), highlighting multiple nonclinical studies which utilize one of Neuron23’s selective, brain-penetrant small molecule TYK2 inhibitors. This research outlines TYK2’s critical role in #neuroinflammation and explores the potential of TYK2 inhibition in #multiplesclerosis. Read more here: https://lnkd.in/gRsN564F

Neuron23 leadership will be attending the AD/PD - Advances in Science & Therapy 2025 International Conference on Alzheimer’s and Parkinson’s Diseases to present results from the healthy volunteer trial of NEU-411. The Phase 1 trial was designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NEU-411 in healthy adults and elderly volunteers for early #Parkinsons disease. For the poster presentation details, visit: https://lnkd.in/gZBMz3sX #ADPD2025 

Tomorrow is #InternationalWomensDay, so we’re celebrating the incredible women of Neuron23 and beyond—scientists, leaders, mothers, daughters, and friends—who inspire, innovate, and shape the world. Here’s to breaking barriers and lifting each other up every day.    As a small token of appreciation, our team has the day off, which also happens to be #EmployeeAppreciationDay, to spend time with their loved ones. 

March is #MSAwarenessMonth, a time to amplify awareness and advance the conversation around #multiplesclerosis (MS). MS is an autoimmune disease where the body's immune system attacks its own central nervous system, leading to a wide range of debilitating symptoms.    At Neuron23, research is driving innovation in targeted therapies aimed at disrupting immune system attacks on myelin. TYK2, a key protein in immune signaling, has emerged as a promising target in the pursuit of better treatments for MS. Continued research and collaboration are critical in the fight against this disease. Click the post below to find resources on how to support the MS community.